Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss important advances in ctDNA and minimal residual disease (MRD) for breast cancer in the neoadjuvant, adjuvant, and advance settings. This research was presented at the 2025 San Antonio Breast Cancer Symposium.
Published
March 17, 2026
Created by
Related Presenters
